<DOC>
	<DOCNO>NCT00288548</DOCNO>
	<brief_summary>We want study effect combination metoprolol ( beta-blocker ) formoterol ( beta-agonist ) long function patient Chronic Obstructive Pulmonary Disease ( COPD ) . There clue beta-blocker , well chosen right dosage , wo n't harm long function patient COPD . Since beta-blocker valuable addition treat patient heart problem would like see category medication available COPD patient future .</brief_summary>
	<brief_title>Metoprolol Formoterol Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>male/female age 4070 inclusive COPD define GOLD criterion FEV1 great equal 60 % predict without medication baseline FEV1 great equal 1.2L 10 pack year hard contraindication use beta blocker able perform technically acceptable pulmonary function test sign informed consent systolic blood pressure equal 130 great instable COPD month visit 1 usage corticosteroid month visit 1 significant pulmonary disease COPD history cancer within last 5 year ( basal cell carcinoma cutaneous squamous cell carcinoma allow ) recent history myocardial infarction use investigational drug within one month six half life ( ever great ) visit 1 contraindication use ipratropiumbromide</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2006</verification_date>
</DOC>